U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07089511) titled 'Cord Blood Platelet Poor Plasma Eye Drops' on July 16.
Brief Summary: Dry eye disease (DED) is a prevalent ocular condition characterized by the disruption of the ocular surface's homeostasis. It affects a significant portion of the population, particularly women and older individuals. The impact of DED on the healthcare system and patients' quality of life is substantial, with approximately 30 million adult patients (14.5%) reporting DED symptoms in the US. Global mapping studies have shown that DED prevalence ranges from 5% to 50% of the population. While chronic instillation of artificial tears is the main treatment strategy for ...